3 / 18
Page 20
Notes:
allied
academies
Ann Clin Trials Vaccines Res. 2017 | Volume 1 Issue 2
Global Vaccines & Vaccination Summit & B2B
November 01-02, 2017 | Toronto, Canada
Anti-energy based unconventional prophylactic HIV/AIDS vaccine provide proof of concept in human
Uniyal Bandana
Shri Radheykrishna Oaj (AIDS) Vaccine Organization, India
T
he human immunodeficiency virus (HIV) pandemic is now in
its fourth decade. With more than 35 million infected in over
thirty years, the HIV pandemic has been a unique challenge to
the scientific community. The development of effective anti-
retroviral therapy has decreased morbidity and mortality of
those infected with HIV, but a comprehensive approach that
includes effective preventive strategies will be needed to
curb this unique pandemic. Vaccine remains the best option,
but the development of a safe and effective preventive HIV
vaccine has defied decades of research. Over 30 products have
been tested in more than 85 trials, but no safe and effective
vaccine has been developed yet. Despite these setbacks, these
decades of research have broadened the understanding of HIV
immunopathogenesis and closer to the goal of a successful
HIV vaccine. Understanding the unique obstacles in HIV
vaccine development has been key in creating breakthroughs
and tracing a path forward. The complexity of this challenge
has required innovative approach to vaccine development.
Prototype HIV-1 vaccine candidates aimed at eliciting humoral
and cellular immune responses have so far failed to protect
against HIV-1 infection or to reduce viral loads after infection
in clinical efficacy studies. A new unconventional basic research
study finds a proof of concept in human when 1:2 dilutions
of HIV-1 infected (positive) serum with anti-energy substance
which lost its infectivity when left for two weeks. This vaccine
strategy is based on energy utilized by the HIV-1 virus for
replication inside host rather than proteinious nature of virus.
No chemical treatment is required for inactivation and killing
of HIV-1 virus. Vaccine was administered intramuscularly to HIV
negative individual. After 3.5 years of follow up study, vaccine
subject does not show any symptoms of HIV-1 infection and
humoral antibody response. Protection was occurred due to
cellular immunity. Sexual transmission of virus does not occur
in study subject while no prevention methods were used during
sexual relationship. In vaccine subject general parameters of
blood (Complete Blood Count) is normal in range. The nature
of HIV infections argues strongly that an effective vaccine
must block infection such that it never becomes established
in vaccinated individuals (i.e., sterilizing protection). The basic
research study provides proof of concept for prophylactic HIV-1
vaccine in human. The study vaccine is safe and effective.
Speaker Biography
Uniyal Bandana is working on my unconventional anti-energy based hypothesis. She is
a young Researcher and her prime aim of life is to prepare preventive vaccine against
HIV/AIDS and struggling for developing her aim in reality. To fulfill her dream, she
developed an organization. She has got Young Scientist B Fellowship in 2008 by the
Department of Science and Technology, New Delhi.
e:
bandana_uni9@yahoo.co.in